Substipharm, a privately held pharmaceutical group, agreed to acquire IMOJEV, a Japanese encephalitis vaccine, from Sanofi, a French multinational pharmaceutical company. Financial terms were not disclosed. “This acquisition provides a massive breakthrough for Substipharm entering a new therapeutic area and reaching new geographies across Asia Pacific. Prevention is a strategic focus for our company, and we aspire to be a recognized partner for vaccines in the long term. This vaccine protects people and saves lives against a disease for which there is currently no curative treatment. With IMOJEV®, Substipharm is taking another step forward to support its rapid growth pattern outside Europe," Leopold Berthier, Substipharm CEO.